Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Ortec International Inc. (NasdaqSC:ORTC)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
3960 Broadway
New York, NY 10032
Phone: (212) 740-6999
Fax: (212) 740-6963
Email: ortecinfo@aol.com
Employees (last reported count): 71
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Healthcare Facilities
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 72%
·Over the last 6 months:
 · 2 insider buys; 4,000  shares
 · 3 insider sells; 84.0K shares
  (1.2% of insider shares)
·Institutional: 47% (169% of float)
(16 institutions)
·Net Inst. Selling: 274.0K shares (+6.37%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Ortec International Inc. is a development stage tissue engineering company that has developed a proprietary and patented technology, called Composite Cultured Skin (CCS), which is used to stimulate the repair and regeneration of human skin. Ortec's Composite Cultured Skin is a two-layered tissue engineered dressing that consists of human derived skin cells, both dermal and epidermal, supported within a porous collagen matrix. The composite matrix is seeded with keratinocytes for epidermal growth and fibroblasts for dermal growth. This active dressing stimulates the repair, replacement and regeneration of human skin. When its CCS is applied to the wound site, it produces a mix of growth factors that stimulates wound closure.
More from Market Guide: Expanded Business Description

Financial Summary
ORTC is a development stage company developing a proprietary technology which consists of a biologically active dressing to stimulate the repair and regeneration of human skin. For the three months ended 3/31/01, revenues decreased 31% to $114 thousand. Net loss increased 32% to $3.5 million. Revenues reflect decreased interest income. Higher loss reflects increased R&D and personnel expenses due to costs associated with increased clinical trial activity.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 5; after tax earnings were -3,753. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Steven Katz, Ph.D., 56
Chairman, CEO
$313K
Costa Papastephanou, Ph.D., 55
Pres
--  
Ron Lipstein, 45
Vice Chairman, CFO, Sec., Treasurer
267K
William Schaeffer, 53
COO
167K
Mark Eisenberg, M.D., 63
Sr. VP, R&D
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqSC:ORTCAs of 31-Aug-2001
Price and Volume
52-Week Low
on 4-Apr-2001
$5.313
Recent Price$7.76 
52-Week High
on 6-Oct-2000
$12.00 
Beta0.33 
Daily Volume (3-month avg)12.0K
Daily Volume (10-day avg)19.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+3.5%
52-Week Change
relative to S&P500
+38.8%
Share-Related Items
Market Capitalization$75.2M
Shares Outstanding9.69M
Float2.70M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$0.61 
Earnings (ttm)-$1.47 
Earnings (mrq)-$0.39 
Sales (ttm)$0.04 
Cash (mrq*)$0.59 
Valuation Ratios
Price/Book (mrq*)12.75 
Price/EarningsN/A 
Price/Sales (ttm)182.29 
Income Statements
Sales (ttm)$403.0K
EBITDA (ttm*)-$12.3M
Income available to common (ttm)-$13.9M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-121.83%
Return on Equity (ttm)-154.06%
Financial Strength
Current Ratio (mrq*)3.98 
Debt/Equity (mrq*)0.17 
Total Cash (mrq)$2.52M
Short Interest
As of 8-Aug-2001
Shares Short1,000 
Percent of Float0.0%
Shares Short
(Prior Month)
3,000 
Short Ratio0.06 
Daily Volume17.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.